# Syncona outlines £250m shareholder return plan and refined investment strategy

- Link: https://www.directorstalkinterviews.com/syncona-outlines-250m-shareholder-return-plan-and-refined-investment-strategy/4121221958
- Published: 2025-10-21T07:50:16+01:00
- Author: Amilia Stone

Further to its strategy update on 19 June, **Syncona plc** (LON:SYNC) has announced
a set of proposals which seek to maximise value for shareholders and to create a
sustainable longer-term structure for all key stakeholders. These refined proposals
come against a background of continued good progress across Syncona’s portfolio,
which is funded to deliver 10 key value inflection points over the next three years,
with the potential to drive significant NAV growth.

Following further extensive consultation with shareholders, whose range of perspectives
have guided the proposals, the Company’s board of directors is proposing:

·     To focus on the return of £250 million of net proceeds to shareholders, from
any potential sales of mature private portfolio companies

o  The Board will determine the structure of future capital returns at the time 
of any realisations, which may include a tender offer, share buyback programme or
special dividend

o  In so doing, it expects to have regard to the quantum of proceeds to be returned,
the Company’s share price and trading dynamics at the time and the wider outlook
across the portfolio, as well as any perspectives from shareholders

·     A new investment objective and policy and capital allocation policy with an
initial focus on realising maximum value from Syncona’s mature portfolio companies
in a timely manner and then to return cash to shareholders, which will mean:

o  Syncona Investment Management Limited’s (“SIML”) team working closely with portfolio
companies to deliver key value inflection points and ensure capital is available
to maximise value

o  Syncona selling portfolio assets only when it is in the best interests of shareholders,
driven by the balance of risk and reward, to maximise value

o  Syncona continuing to make selective new investments in early-stage companies
developing exceptional academic science, up to an aggregate of 5% of the Company’s
last-reported NAV

·     Once £250 million has been returned to shareholders, Syncona will return to
focusing on achieving long-term capital appreciation by funding new life science
investments and existing portfolio companies

·     The Board intends to consult shareholders regarding a new capital allocation
policy in advance of satisfaction of the £250 million return

·     Shareholders will also be consulted on new long-term incentive arrangements
for SIML employees to align SIML’s interests with the proposed investment objective
and policy

·     A change to the composition of the Board in light of the proposed investment
objective and policy

·     An intention to optimise the cost base across the group to align with the 
proposed investment objective and policy

·     To support SIML in seeking to establish a new private fund, independent from
Syncona, to diversify its funding sources

The Board has concluded that there is currently limited appetite amongst shareholders
for immediate capital returns from realisations at a significant discount to NAV.

Following the consultation on the new long-term incentive arrangements, the Company
will seek shareholder approvals to implement the new investment objective and policy,
and incentive scheme.

> **Melanie Gee, Chair of Syncona, commented**: “Today’s set of proposals provides
> the Company and SIML with a clear initial focus to maximise value in the portfolio
> and return cash to shareholders from the realisation of mature portfolio assets.
> We are very grateful to our shareholders who have engaged extensively with the
> process and whose views have guided these refined proposals. The Board is confident
> in the SIML team’s ability to work with our portfolio companies to deliver the
> key value inflection points and realisations, which would have the potential to
> generate significant proceeds for shareholders, and we look forward to returning
> £250m in a timely manner.  We also recognise the importance of the SIML team’s
> ongoing contribution to a thriving life science sector here in the UK. We believe
> the proposals outlined today are in the best interests of our key stakeholders.”

> **Chris Hollowood, Chief Executive Officer of SIML, added**: _“_The portfolio 
> is well positioned to deliver NAV growth over the medium term, and we are committed
> to ensuring shareholders benefit from the potential returns available as markets
> stabilise_._ We believe the revised investment policy, which we are firmly supportive
> of and aligned with, will deliver value for all stakeholders. Moreover, we remain
> confident in the long-term potential in the sector and believe there remains a
> significant opportunity to build late-stage life science companies that can deliver
> attractive returns for our shareholders, after £250 million has been returned 
> from realisations. During this initial period, where our investment focus is predominantly
> on realising maximum value from portfolio assets, we will seek to raise a private
> fund, which would create a sustainable long-term platform to match the development
> cycle in life science and support us in maximising value for Syncona’s shareholders.”

**Background to the refined proposals**

In June, following shareholder engagement, the Board announced it had undertaken
a comprehensive review of strategic options to maximise value for shareholders. 
The Company outlined that a potential new investment objective and policy, to focus
on returning proceeds of realisations to its shareholders, would be reviewed by 
the Board after significant proceeds had been returned to shareholders or, at the
latest, after three years. Any material amendment to the Company’s investment objective
and policy at that time would have required further FCA and shareholder approval.
The Board also announced it was looking at options to accelerate realisations, which
may have included a sale of a small portion of its interests in certain of its portfolio
companies at a discount to NAV.

This initial set of proposals have been subject to further consultation with shareholders
by the Company and SIML. The Board has concluded there is currently limited appetite
amongst shareholders for immediate capital returns from realisations at a significant
discount to NAV, whilst a number of the Company’s shareholders and other market 
participants, particularly in the life sciences sector, considered the proposals
as putting the Company into inevitable run-off. 

The Board wishes to make clear its intention to return to a policy of investing 
in new portfolio companies to achieve long-term capital appreciation once £250 million
has been returned to shareholders. The decision to continue to pursue small selective
investments into new companies also means that the Company will preserve a pipeline
of early portfolio assets, which have the potential to underpin future growth. These
refinements will  enable SIML to remain active market participants, and to help 
avoid any undue negative impact on the value of the portfolio companies through 
impaired realisations and unduly dilutive syndications.

**New investment objective and policy with an initial focus on realising maximum
value from portfolio assets in a timely manner and then returning cash to shareholders**

Syncona’s proposed investment objective is to achieve superior long-term capital
appreciation by selectively investing in growth opportunities in the life sciences
sector, with an initial focus on realising maximum value from its mature portfolio
assets in a timely manner.

The Company’s initial priority is to maximise value from its mature portfolio companies
in a managed and considerate manner to return £250 million in aggregate to its shareholders.
The Board will determine the structure of future capital returns at the time of 
any sales of private portfolio companies, which may include a tender offer, share
buyback programme or special dividend. In choosing the appropriate structure, the
Board expects to have regard for the quantum of proceeds to be returned, the Company’s
share price and trading dynamics at the time, the wider outlook across the portfolio,
as well as any perspectives from shareholders.

In order to achieve its initial objective of returning cash to shareholders, the
Company will make further investments to provide additional funding to its existing
portfolio companies.

The SIML team will continue to drive the value of the life science portfolio by 
focusing on the delivery of key value inflection points. Syncona’s c.£250 million
capital pool^([1](https://www.londonstockexchange.com/#_ftn1)) ensures that the 
portfolio is funded to deliver on 10 key value inflection points over the next three
years, which have the potential to drive significant NAV growth. The SIML team will
maintain a proactive portfolio management approach and ensure capital is available
to maximise value, whilst avoiding quick, value destructive exit options. The Company
will only divest interests in portfolio companies when it is in the best interests
of shareholders.

The Company will, during this time, also make selective investments into new pre-
clinical therapeutic programmes from world-leading academic institutions. These 
investments will be limited, in aggregate and at the time of such investments, to
an amount equal to 5% of the Company’s last-reported NAV prior to approval of the
new investment objective and policy. These investments will provide a pipeline of
early portfolio assets, which have the potential to underpin future growth. 

**Returning to focus on long-term capital appreciation**

Once £250 million of proceeds has been return to shareholders, Syncona will return
to focusing on achieving long-term capital appreciation by funding new life science
businesses and existing portfolio companies, seeking to build a diversified portfolio
of 20-25 companies. As a consequence of the proposed new investment objective and
policy, the Board will, following guidance from SIML, no longer seek to achieve 
its previously published 2032 targets, including the ambition to grow assets to 
£5 billion by 2032 and create three new companies per annum.

**Ensuring Syncona is well positioned for successful delivery of its new strategy**

_Proposed long-term incentive arrangements_

The Company will undertake a consultation with shareholders on the implementation
of new long-term incentive arrangements for SIML employees to align SIML’s interests
with the proposed new investment objective and policy.

The period for making awards under the existing long term incentive plan (“LTIP”)
is coming to an end and the scheme is closed to further issuances. Awards made under
any new scheme would exist concurrently with awards previously granted under the
current LTIP, and are anticipated to be based on the realised value of current portfolio
assets in excess of the Company’s NAV as at 30 September 2025. It is the Board’s
intention to ensure that this combination appropriately incentivises the SIML team
while maintaining a cap on SIML’s aggregate potential profit share.  

_Potential private fund to be managed by SIML, independent of the Company_

The Board supports the SIML team in seeking to raise a new private fund to deliver
its UK based life sciences model, which will invest on the basis of the SIML team’s
create, build, and scale model.  The additional fund, managed by the SIML team, 
will diversify funding sources, and seek to attract funding from investors who are
unable to invested in a listed company, also diversifying the financial risk across
the group. The Board believes this will be beneficial to the Company’s portfolio
and should drive superior returns for its shareholders.

Discussions between the SIML team and third parties regarding a new private fund
have commenced. If a new fund is established, it is the intention of the Board to
establish protections for the Company’s shareholders in relation to any potential
conflicts that may arise from the SIML team managing two funds. Furthermore, it 
is the intention of the Board to facilitate the separation of SIML, on suitable 
terms, to enable the SIML team to manage both the Company’s portfolio and that of
the new fund; the Board intends to work to enable the separation of SIML efficiently.
Should a new private fund be raised, the Board intends to explore the possibility
for shareholders to roll their interests in the Company into the new private fund.

**Rigorous focus on costs across the group**

_Changes to the composition of the Board_

In light of the proposed investment objective and policy and following the departure
of one non-executive director earlier in the year, the Board intends to further 
reduce the overall number of non-executive Directors on the Board to five, which
will in due course include a new non-executive director with investment company 
expertise and experience.

_Optimising the cost base_

More broadly, the Board is focused on optimising the cost base across both the Company
and SIML to align with the proposed investment objective and policy. As part of 
this, SIML will continue to prudently manage its annual budget and seek opportunities
to drive cost efficiencies across the business.

_Donations to the Syncona Foundation_

The Board has also agreed, given the proposed change of strategy, that donations
to the Syncona Foundation should be reduced to 0.25% of NAV (calculated on a monthly
basis) for the next three financial years, effective after the current financial
year.

**Share buyback arrangements**

In light of the strategy update, the Board has decided not to renew the prior share
buyback arrangements with Deutsche Numis, which came to an end on 18 June 2025, 
and will not pursue any further buybacks at this time. The remaining £5.4 million
that had previously been allocated to buybacks will be deployed in line with the
proposed investment objective and policy outlined above.

**Timing for next steps**

The proposed new investment objective and policy has been approved by the Financial
Conduct Authority but will require shareholder approval before being implemented.
The full text of the proposed new investment objective and policy and accompanying
capital allocation policy is set out in the appendix to this announcement.

Syncona intends to make a further announcement on the proposals set out above once
it has completed the shareholder consultation on the new long-term incentive arrangements
for the SIML team, and shortly thereafter will convene a General Meeting at which
the change of investment objective and policy, and the new long-term incentive arrangements
package, will be proposed.

Share on:
